Royalty Pharma plc
For the period ended Jun 30, 2025. Filed Aug 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. EXHIBITS
The following exhibits are filed as a part of this Quarterly Report on Form 10-Q:
| Exhibit No. | Description of Exhibit |
| 3.1 | Amended and Restated Articles of Association of Royalty Pharma plc |
| 3.2 | Amended and Restated Articles of Association of Royalty Pharma Holdings Ltd |
| 10.1 | Joinder, Release and First Amendment to Loan Agreement and Loan Documents |
| 10.2 | Amended and Restated Exchange Agreement, dated as of May 16, 2025 |
| 10.3* | Form of Executive Offer Letter |
| 10.4* | Form of Deed of Indemnity |
| 10.5 | Royalty Pharma plc 2025 Equity Incentive Plan |
| 10.6* | Fourth Supplemental Indenture, dated as of June 9, 2025, Royalty Pharma plc, Royalty Pharma Holdings Ltd and Wilmington Trust, National Association, as Trustee |
| 31.1* | Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act |
| 31.2* | Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act |
| 32* | Certifications of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act |
| 101.INS | XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) |
| 101.SCH | XBRL Taxonomy Extension Schema Document |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase |
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |
- Filed or furnished herewith
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ROYALTY PHARMA PLC
(Registrant)
/s/ Pablo Legorreta
Pablo Legorreta
Chief Executive Officer
Date: August 6, 2025
/s/ Terrance Coyne
Terrance Coyne
Chief Financial Officer
Date: August 6, 2025
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.